ESPEYB15 15 Editor’s Choice New data: hormonal contraception and breast cancer (1 abstracts)
15.9 Contemporary Hormonal Contraception and the Risk of Breast Cancer
Morch LS , Skovlund CW , Hannaford PC , Iversen L , Fielding S & Lidegaard O
Rigshospitalet, the Juliane Marie Center, Department of Gynecology, University of Copenhagen, Copenhagen, Denmark
To read the full abstract: N Engl J Med 2017;377:2228-2239
Paediatric endocrinologists often prescribe oral hormonal contraception preparations as these are convenient options for the management of various conditions in adolescent girls (e.g. polycystic ovary syndrome features, hypogonadism). Therefore, we should understand the possible adverse effects. This huge national database study data provides robust estimates of the relatively small excess risk of breast cancer. Notably, there was little difference between the main types of combined oral contraceptive preparation on breast cancer risk, whether monophasic or triphasic, containing norethesterone or levonorgestrel, or even by estrogen dose. Furthermore, breast cancer risk was also increased with use of progestin-only products. Risk of breast cancer increased with duration of treatment, and appeared to rapidly disappear after discontinuation of relatively short treatment periods (<5 years). Hence, these findings are highly reassuring. Tt would be helpful to have similar robust information on risks of thromboembolism.
Volume 15
Article tools
My recent searches
My recently viewed abstracts
Authors
ESPE Yearbook of Paediatric Endocrinology
ISSN 1662-4009 (Online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more